Introduction Although cost-utility analyses are frequently used to estimate treatment outcomes
for type 2 diabetes, utilities are not available for key medication-related attributes. The …

OBJECTIVES:: This study examined patterns of antidiabetic treatment among individuals
with type 2 diabetes in Germany and investigated potential differences in attainment of …

Background In the US, 26 % of women aged ≥65 years, and over 50 % of women aged ≥85
years are affected with postmenopausal osteoporosis (PMO). Each year, the total direct …

Background Prior to using a generic patient-reported outcome measure (PRO), the measure
should be validated within the target population. The purpose of the current study was to …

BACKGROUND: Weight gain is a common side effect of many therapies for type 2 diabetes (T2DM).
Selecting utility values for incorporation into cost-utility analyses (CUAs) of T2DM …

Objectives: The aim of this study was to evaluate the long-term clinical and economic outcomes
associated with exenatide or insulin glargine, added to oral therapy in individuals with …

Objective: Based on randomized controlled trials (RCTs), non-fatal myocardial infarction (MI)
rates range between 9 and 15 events per 1000 person-years, ischemic stroke between 4 …

Background Ivabradine is a heart rate–lowering agent approved to reduce the risk of
hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding …

The purpose of this study was to describe the patterns of antidiabetic medication use and
the cost of testing supplies in Canada using information collected by Saskatchewan's Drug …

The objective of this study was to assess current treatment patterns, blood glucose test strip
usage, and treatment compliance in patients with type 2 diabetes mellitus (T2DM) in primary …